The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 1.46 — grey zone — between safe and distressedWatch
- Earnings-manipulation signal · Beneish M -2.63 — no flag raisedOK
- Earnings quality 95/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as NEOGENOMICS INC reports it. History and quarterly detail are in the app.
- Client direct billing$518.8M
- Commercial insurance$117.5M
- Medicare and other government$90.9M
- Self-pay$114K
Leadership changes
From NEOGENOMICS INC's own filings, the day they're filed.
- Jack Kenny · director · departureeff. 2025-12-31
- Alison L. Hannah · director · departureeff. 2025-12-31
- Elizabeth Floegel · Directors · departureeff. 2025-08-05
Latest filings
- 8-K · Company announcement2026-08-11
- 10-Q · Quarterly report2026-07-28
- 8-K · Company announcement2026-07-28
- 8-K · Company announcement2026-07-20
- 8-K · Company announcement2026-06-25
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about NEOGENOMICS INC, every answer cited to the official filings🔒
- The Intelligence Brief — added when NEOGENOMICS INC's brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.